SavedAdd your journal

Journals / Eskisehir Medical Journal / 2024 / Volume: 5 Issue: 3

POLYPHARMACY EXPERIENCE IN GERIATRIC HEMATOLOGY

GERİATRİK HEMATOLOJİDE POLİFARMASİ DENEYİMİ

Abdulkadir Karısmaz(University of Health Science, Istanbul Training and Research Hospital, Department of Hematology)0000-0002-5556-7501
Istemi Serın(İbrahim Çeçen Üniversitesi, Ağrı Eğitim ve Araştırma Hastanesi)0000-0003-1855-774X
Ceyda Aslan(UNIVERSITY OF HEALTH SCIENCES, KOCAELİ DERİNCE HEALTH RESEARCH CENTER)0000-0002-9692-7761
Damla Kızıl(SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.)0000-0002-4755-0443
Rafet Eren(BİRUNİ ÜNİVERSİTESİ, BİRUNİ UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-0973-6279
Elif Suyani(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ADANA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-2515-671X
Pages
—
Publication Date
2024-11-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The probability of overall survival at the end of the follow-up was 36% in patients receiv-ing ≤ 6 drugs, and 46% in patients receiving > 6 drugs (p=0.271).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Polypharmacy in hematological malignancies is also a research area with very little literature data.
📊
Key Findings & Data:Method: The data of 91 patients, who were ≥ 60 years old, with the diagnosis of a hematological malignancy was analyzed retrospectively.
💡
Conclusion & Impact:Results: The probability of overall survival at the end of the follow-up was 36% in patients receiv-ing ≤ 6 drugs, and 46% in patients receiving > 6 drugs (p=0.271).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Polypharmacy · treatment · response

Abstract

Background: Polypharmacy in hematological malignancies is also a research area with very little literature data. The development of personalized treatment approaches in this patient group is con-siderable for future needs. In our study, the aim was to investigate the effects of polypharmacy on treatment response, and survival in elderly patients with different hematological malignancies. Method: The data of 91 patients, who were ≥ 60 years old, with the diagnosis of a hematological malignancy was analyzed retrospectively. Results: The probability of overall survival at the end of the follow-up was 36% in patients receiv-ing ≤ 6 drugs, and 46% in patients receiving > 6 drugs (p=0.271). In subgroup analysis regarding the diagnosis of the patients, there was no difference between subgroups. Conclusion: The polypharmacy is indispensable in a number of old patients with comorbidites, and this situation would not hinder the physicians from treating those patients with the diagnosis of he-matological maligancies, at least the indolent types.

Özet

Amaç: Hematolojik malignitelerde polifarmasi, literatür verileri çok az olan bir araştırma alanıdır. Bu hasta grubunda kişiselleştirilmiş tedavi yaklaşımlarının geliştirilmesi gelecekteki ihtiyaçlar açısından dikkate değerdir. Çalışmamızda farklı hematolojik maligniteleri olan yaşlı hastalarda polifarmasinin tedaviye yanıt ve sağkalım üzerine etkilerinin araştırılması amaçlandı. Yöntemler: Hematolojik malignite tanısı alan 60 yaş ve üzeri 91 hastanın verileri retrospektif olarak incelendi. Bulgular: Takip sonunda genel sağkalım olasılığı ≤ 6 ilaç alan hastalarda %36, > 6 ilaç alan hastalarda %46 idi (p=0,271). Hastaların tanılarına ilişkin alt grup analizinde alt gruplar arasında fark yoktu. Sonuç: Komorbiditesi olan birçok yaşlı hastada polifarmasi vazgeçilmezdir ve bu durum hekimlerin hematolojik malignite tanısı alan hastaları, en azından düşük dereceli tiplerini tedavi etmelerine engel olmayacaktır.

🔖

Cite This Article

Karısmaz, A., Serın, I., Aslan, C., Kızıl, D., Eren, R., Suyani, E. (2024). POLYPHARMACY EXPERIENCE IN GERIATRIC HEMATOLOGY. Eskisehir Medical Journal, Volume: 5 Issue: 3. https://ajindex.com/articles/1614291

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:230.
  2. Caughey GE, Ramsay EN, Vitry AI, et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Community Health 2010;64:1036-42.
  3. Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ. 2008;336:606-9.
  4. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008;3:383-9.
  5. Cadogan CA, Ryan C, Hughes CM. Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many. Drug Saf 2016;39:109-16.
  6. Sirois C, Laroche ML, Guénette L, Kröger E, Cooper D, Émond V. Polypharmacy in multi-morbid older adults: protocol for a systematic review. Syst Rev 2017;6:104.
  7. Payne RA. The epidemiology of polypharmacy. Clin Med (Lond) 2016;16:465-69.
  8. Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric im-pairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol 2014;93:1031-40.
  9. Sedrak MS, Freedman RA, Cohen HJ, et al. Cancer and Aging Research Group (CARG). Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA Cancer J Clin 2021;71:78-92.
  10. Cheson BD, Fisher RI, Barrington SF, et al. Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Can-cer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommen-dations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-68.
  11. Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book 2016;35:418-23.
  12. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745-60.
  13. Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient Character-istics Associated with Polypharmacy and Inappropriate Prescribing of Medications among Older Adults with Cancer. J Geriatr Oncol 2012;3:228-237.
  14. Caillet P, Canoui-Poitrine F, Vouriot J, et al. Comprehensive geriatric assessment in the deci-sion-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011;29:3636-42.
  15. Iurlo A, Nobili A, Latagliata R, et al. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 2016;7:80083-90.
  16. Elliot K, Tooze JA, Geller R, et al. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res 2014;38:1184-90.
  17. Sugidono M, Lo M, Young R, et al. Impact of Polypharmacy Prior to Allogeneic Hematopoiet-ic Stem Cell Transplantation in Older Adults. Transplant Cell Ther 2021;27:344.
  18. Singh H, Kanapuru B, Smith C. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US Food and Drug Administration. J Clin Oncol 2017;35.
  19. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin On-col.2004;22:4626-31.
  20. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30:2036-8.